Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients

被引：0
|
作者：
R Launois
L Riou Franca
B Guidet
P Aegerter
X Huet
P Meshaka
P Pinton
机构：
[1] REES France,Biostatistique et Informatique médicale
[2] Réseau d'Evaluation en Economie de la Santé,undefined
[3] Hôpital Saint Antoine,undefined
[4] Hôpital Ambroise Paré,undefined
[5] Laboratoire Lilly France,undefined
来源：
Critical Care | / 6卷 / Suppl 1期
关键词：
Severe Sepsis; Cost Effectiveness Ratio; Expected Cost; Drotrecogin Alfa; Differential Cost;
D O I：
10.1186/cc1570
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, G
    van Hout, B
    CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
  • [2] Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis
    Costa V.
    Brophy J.M.
    BMC Anesthesiology, 7 (1)
  • [3] Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
    Green, C
    Dinnes, J
    Takeda, AL
    Cuthbertson, BH
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2006, 22 (01) : 90 - 100
  • [4] Timing of drotrecogin alfa (activated) treatment in severe sepsis
    Goda Choi
    Anne-Cornélie JM de Pont
    Marcus J Schultz
    Critical Care, 10
  • [5] Timing of drotrecogin alfa (activated) treatment in severe sepsis
    Choi, Goda
    de Pont, Anne-Cornelie J. M.
    Schultz, Marcus J.
    CRITICAL CARE, 2006, 10 (04):
  • [6] Clinical trials in severe sepsis with drotrecogin alfa (activated)
    Pierre-François Laterre
    Critical Care, 11
  • [7] Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
    Gordon R Bernard
    William L Macias
    David E Joyce
    Mark D Williams
    Joan Bailey
    Jean-Louis Vincent
    Critical Care, 7
  • [8] Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
    Bernard, GR
    Macias, WL
    Joyce, DE
    Williams, MD
    Bailey, J
    Vincent, JL
    CRITICAL CARE, 2003, 7 (02) : 155 - 163
  • [9] Use of drotrecogin alfa (activated) in older patients with severe sepsis
    Alexander, SL
    Ernst, FR
    PHARMACOTHERAPY, 2006, 26 (04): : 533 - 538
  • [10] Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
    Jan O Friedrich
    Neill KJ Adhikari
    Maureen O Meade
    Critical Care, 10
12345